When will there be new therapies for Parkinson’s? Are scientists studying new ways to treat it? To find out, view this one-hour PD ExpertBriefing, led by David G. Standaert, M.D., Ph.D., of the University of Alabama at Birmingham.
- Provide an understanding of the “pipeline," e.g., introduce the concepts of target identification and validation, drug development and clinical trials
- Review recently approved medications for Parkinson’s
- Assess short-term expectations for the pipeline – potential new drugs for Parkinson’s that are already under investigation in clinical trials
- Discuss long-term plans for the pipeline – potential drugs and approaches for treatment not yet in clinical trials
Dr. Standaert sees patients in a weekly clinic and oversees many clinical trials for new treatments of Parkinson's disease. His research laboratory works on understanding both the root causes of Parkinson’s disease as well as the origin of the disabling symptoms that appear after long term treatment of the disease. Recently, his group has focused on approaches to reducing the toxicity of synuclein in animal models of Parkinson's disease, and the role of neuroinflammatory reactions in disease progression.
Dr. Standaert previously served on the faculty of Massachusetts General Hospital (MG) as Director of the MGH/MIT Udall Center of Excellence in Parkinson’s Disease Research and as a Chair of the MGH Institutional Review Board (IRB). He graduated from Harvard College and received his M.D. and Ph.D. degrees from Washington University in St. Louis. He completed a one-year internship in Medicine followed by a three-year residency in Neurology at the University of Pennsylvania. He was appointed as a Howard Hughes Medical Institute Physician Research Fellow, and completed a three-year research and clinical fellowship in Neurology (Movement Disorders) at Harvard Medical School and Massachusetts General Hospital.
He is a member of the Scientific Advisory Boards of the Michael J. Fox Foundation for Parkinson Research, the American Parkinson Disease Association and the Bachmann-Strauss Dystonia and Parkinson Foundation.